Table 3.

AEs (≥1% in any treatment group; safety set)

AE category (MedDRA PT presented by SOC), n (%)	Olopatadine HCl 0.77% (n=164)	Olopatadine 0.2% (n=167)	Vehicle (n=117)
Eye disorders
Eye irritation	2 (1.2)	0	1 (0.9)
Vision blurred	0	1 (0.6)	2 (1.7)
VA reduced	2 (1.2)	1 (0.6)	0
Infections and infestations
Gastroenteritis viral	3 (1.8)	0	0
Nervous system disorders
Dysgeusia	2 (1.2)	0	0
Respiratory, thoracic, and mediastinal disorders
Cough	0	0	2 (1.7)

Note: Olopatadine HCl 0.77% refers to olopatadine HCl 0.77% (equivalent to 0.7% olopatadine free base) treatment group.

Abbreviations: AEs, adverse events; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; SOC, system organ class; VA, visual acuity.